Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Alternative splicing of the pyruvate kinase M gene (PK-M) can generate the M2 isoform and promote aerobic glycolysis and tumor growth. However, the cancer-specific alternative splicing regulation of PK-M is not completely understood. Here, we demonstrate that PK-M is regulated by reciprocal effects on the mutually exclusive exons 9 and 10, such that exon 9 is repressed and exon 10 is activated in cancer cells. Strikingly, exonic, rather than intronic, cis-elements are key determinants of PK-M splicing isoform ratios. Using a systematic sub-exonic duplication approach, we identify a potent exonic splicing enhancer in exon 10, which differs from its homologous counterpart in exon 9 by only two nucleotides. We identify SRSF3 as one of the cognate factors, and show that this serine/arginine-rich protein activates exon 10 and mediates changes in glucose metabolism. These findings provide mechanistic insights into the complex regulation of alternative splicing of a key regulator of the Warburg effect, and also have implications for other genes with a similar pattern of alternative splicing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 6×
“PK-M2 is expressed in cancer cells, as well as in fetal and undifferentiated adult tissues, and is allosterically regulated by fructose-1,6-bisphosphate (FBP) and can interact with tyrosine-phosphorylated signaling proteins (Christofk et al., 2008a, b).”
BackgroundInfluentialSelf-citationListening to silence and understanding nonsense: exonic mutations that affect splicing
Cartegni, L., Chew, S. L., & Krainer, A. R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg775 · Cited by 2,209 · cited 2×
“The use of two wobble nucleotides to code for a key splicing signal illustrates the impact of sequence changes that would be translationally neutral, except that they drastically affect the structure of the resulting protein by changing alternative splicing of the entire exon (Cartegni et al., 2002).”
BackgroundSelf-citationHnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
David, C. J., Chen, M., Assanah, M., Canoll, P., & Manley, J. L. (2010) · Nature · doi:10.1038/nature08697 · Cited by 1,179 · cited 11×
“In a previous study, SRSF3 knockdown led to a smaller increase in PK-M1, which was deemed not significant (David et al., 2010), but this could have reflected weaker knockdown and/or negative selection resulting from the use of a stably transfected shRNA.”
BackgroundInfluentialTyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T.-W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000431 · Cited by 784 · cited 1×
“The growth signal-mediated inhibition of PK-M2 activity contributes to cancer cell growth by decreasing carbon flux through the catabolic glycolytic pathway, allowing accumulated upstream intermediates to be shunted to anabolic pathways to facilitate cell proliferation (Hitosugi et al., 2009).”
BackgroundSelf-citationClower, C. V., Chatterjee, D., Wang, Z., Cantley, L. C., Vander Heiden, M. G., & Krainer, A. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914845107 · Cited by 424 · cited 15×
“Given that hnRNPA1 does affect exon 9 inclusion in vivo (Clower et al., 2010; David et al., 2010), hnRNPA1-induced exon 9 repression could occur either indirectly—through regulation of a splicing factor that in turn regulates PK-M alternative splicing—or through additional cis-elements located…”
BackgroundMethodInfluentialSelf-citationSFmap: a web server for motif analysis and prediction of splicing factor binding sites
Paz, I., Akerman, M., Dror, I., Kosti, I., & Mandel-Gutfreund, Y. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq444 · Cited by 102
Self-citation
Cited by
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
“In cancer cells, the expression of splicing factors favors the generation of PKM2 mRNA (62–65).”
Mechanisms and Regulation of Alternative Pre-mRNA Splicing
Lee, Y., & Rio, D. C. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034316 · Cited by 1,291
Pyruvate kinase: Function, regulation and role in cancer
Israelsen, W. J., & Vander Heiden, M. G. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.08.004 · Cited by 589
Self-citationRNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.025 · Cited by 549
“The regulation of PKM splicing is dependent on multiple splicing factors that bind within the PKM1 and PKM2 exons to promote or suppress their inclusion in the mature transcript (Clower et al., 2010; David et al., 2010; Wang et al., 2012).”
Urbanski, L. M., Leclair, N., & Anczuków, O. (2018) · WIREs RNA · doi:10.1002/wrna.1476 · Cited by 389
Emerging roles of PKM2 in cell metabolism and cancer progression
Luo, W., & Semenza, G. L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.010 · Cited by 376
PKM2 and cancer: The function of PKM2 beyond glycolysis
DONG, G., MAO, Q., XIA, W., XU, Y., WANG, J., XU, L., & JIANG, F. (2016) · Oncology Letters · doi:10.3892/ol.2016.4168 · Cited by 325
Misregulation of Pre-mRNA Alternative Splicing in Cancer
Zhang, J., & Manley, J. L. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0253 · Cited by 307
Splicing-factor alterations in cancers
Anczuków, O., & Krainer, A. R. (2016) · RNA · doi:10.1261/rna.057919.116 · Cited by 302
Self-citationGlycolytic reliance promotes anabolism in photoreceptors
Chinchore, Y., Begaj, T., Wu, D., Drokhlyansky, E., & Cepko, C. L. (2017) · eLife · doi:10.7554/elife.25946 · Cited by 191
“To evaluate this possibility, we examined the expression of Srsf3, a splicing factor known to promote inclusion of the M2 exon (Wang et al., 2012), and Ptbp1, known to repress the M1 exon inclusion (Chen et al., 2012) (Figure 3—figure supplement 4).”
BackgroundTherapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids
Wan, L., Kral, A. J., Voss, D., Schäfer, B., Sudheendran, K., Danielsen, M., Caruthers, M. H., & Krainer, A. R. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0070 · Cited by 17
Self-citationRNA-coupled CRISPR screens reveal ZNF207 as a regulator of LMNA aberrant splicing in progeria
Behera, A. K., Kim, J. J., Kordale, S., Pekovic, F., Damodaran, A. P., Kumari, B., Vidak, S., Dickson, E., Xiao, M.-S., Duncan, G., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2025.12.003 · Cited by 6
Metadata
- Authors
- Wang, Z., Chatterjee, D., Jeon, H. Y., Akerman, M., Vander Heiden, M. G., Cantley, L. C., & Krainer, A. R.
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11-01
- Volume
- 4
- Issue
- 2
- Pages
- 79-87
- ISSN
- 1674-2788 (ISSN-L)
- 1759-4685
- OpenAlex
- W2102188028
- Cited by
- 124
- References
- 6
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.